| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
|
Wakelee, Heather A
|
|
2017
|
18 |
12 |
p. 1610-1623
|
article
|
| 2 |
ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
|
Bestvina, Christine M
|
|
2017
|
18 |
12 |
p. 1555-1556
|
article
|
| 3 |
An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report
|
Spratt, Daniel E
|
|
2017
|
18 |
12 |
p. e720-e730
|
article
|
| 4 |
A polymorphous bullous dermatosis
|
Drahy, Faustine
|
|
2017
|
18 |
12 |
p. e776
|
article
|
| 5 |
Bevacizumab in adjuvant treatment of non-small-cell lung cancer
|
Weiss, Jared
|
|
2017
|
18 |
12 |
p. 1558-1560
|
article
|
| 6 |
Biomarkers for subtypes of pancreatic ductal adenocarcinoma
|
Venkatesan, Priya
|
|
2017
|
18 |
12 |
p. e718
|
article
|
| 7 |
Bosutinib more effective than imatinib in CML
|
Gourd, Elizabeth
|
|
2017
|
18 |
12 |
p. e716
|
article
|
| 8 |
Breast thermography alone no substitute for mammography
|
Gourd, Elizabeth
|
|
2017
|
18 |
12 |
p. e713
|
article
|
| 9 |
Brentuximab vedotin for advanced Hodgkin's lymphoma
|
Fanale, Michelle A
|
|
2017
|
18 |
12 |
p. 1566-1568
|
article
|
| 10 |
Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study
|
Fidler, Miranda M
|
|
2017
|
18 |
12 |
p. 1579-1589
|
article
|
| 11 |
Cancer in two Renaissance families
|
Charlier, Philippe
|
|
2017
|
18 |
12 |
p. e707
|
article
|
| 12 |
Carcinogenicity of benzene
|
Loomis, Dana
|
|
2017
|
18 |
12 |
p. 1574-1575
|
article
|
| 13 |
Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis
|
Daver, Naval
|
|
2017
|
18 |
12 |
p. 1571-1573
|
article
|
| 14 |
Clinical decision making: more than just an algorithm
|
The Lancet Oncology,
|
|
2017
|
18 |
12 |
p. 1553
|
article
|
| 15 |
Correction to Lancet Oncol 2017; 18: 1061–75
|
|
|
2017
|
18 |
12 |
p. e711
|
article
|
| 16 |
Correction to Lancet Oncol 2017; 18: 1493–1501
|
|
|
2017
|
18 |
12 |
p. e711
|
article
|
| 17 |
Correction to Lancet Oncol 2016; 17: 1637–38
|
|
|
2017
|
18 |
12 |
p. e711
|
article
|
| 18 |
Correction to Lancet Oncol 2017; 18: 1555–56
|
|
|
2017
|
18 |
12 |
p. e711
|
article
|
| 19 |
Defining a global research and policy agenda for betel quid and areca nut
|
Mehrtash, Hedieh
|
|
2017
|
18 |
12 |
p. e767-e775
|
article
|
| 20 |
Defining precision medicine
|
Burki, Talha Khan
|
|
2017
|
18 |
12 |
p. e719
|
article
|
| 21 |
De-novo and acquired resistance to immune checkpoint targeting
|
Syn, Nicholas L
|
|
2017
|
18 |
12 |
p. e731-e741
|
article
|
| 22 |
Die young with me
|
Denny, Victoria
|
|
2017
|
18 |
12 |
p. 1576
|
article
|
| 23 |
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
|
Ferolla, Piero
|
|
2017
|
18 |
12 |
p. 1652-1664
|
article
|
| 24 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
|
Vilgrain, Valérie
|
|
2017
|
18 |
12 |
p. 1624-1636
|
article
|
| 25 |
European position statement on lung cancer screening
|
Oudkerk, Matthijs
|
|
2017
|
18 |
12 |
p. e754-e766
|
article
|
| 26 |
Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions
|
Chavez-MacGregor, Mariana
|
|
2017
|
18 |
12 |
p. 1568-1569
|
article
|
| 27 |
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited
|
Nguyen, Huy Tram N
|
|
2017
|
18 |
12 |
p. e708
|
article
|
| 28 |
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply
|
Weller, Michael
|
|
2017
|
18 |
12 |
p. e709-e710
|
article
|
| 29 |
Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma?
|
Kaseb, Ahmed Omar
|
|
2017
|
18 |
12 |
p. 1560-1561
|
article
|
| 30 |
Gut microbiome and immunotherapy response
|
Burki, Talha Khan
|
|
2017
|
18 |
12 |
p. e717
|
article
|
| 31 |
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
|
Brahmer, Julie R
|
|
2017
|
18 |
12 |
p. 1600-1609
|
article
|
| 32 |
Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
|
Arbyn, Marc
|
|
2017
|
18 |
12 |
p. 1665-1679
|
article
|
| 33 |
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
|
Eichenauer, Dennis A
|
|
2017
|
18 |
12 |
p. 1680-1687
|
article
|
| 34 |
Ischaemia in liver resection predicts cancer-specific survival
|
Gourd, Elizabeth
|
|
2017
|
18 |
12 |
p. e712
|
article
|
| 35 |
Island
|
Burki, Talha Khan
|
|
2017
|
18 |
12 |
p. 1578
|
article
|
| 36 |
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
|
Shaw, Alice T
|
|
2017
|
18 |
12 |
p. 1590-1599
|
article
|
| 37 |
Lung cancer in Asian women and health system implications for Australia
|
Emery, Jon David
|
|
2017
|
18 |
12 |
p. 1570-1571
|
article
|
| 38 |
Make Blood Cancer Visible
|
Kennedy, Anna
|
|
2017
|
18 |
12 |
p. 1577
|
article
|
| 39 |
Missing a GOLDen opportunity in gastric cancer
|
Smyth, Elizabeth
|
|
2017
|
18 |
12 |
p. 1561-1563
|
article
|
| 40 |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|
Martin, Miguel
|
|
2017
|
18 |
12 |
p. 1688-1700
|
article
|
| 41 |
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Bang, Yung-Jue
|
|
2017
|
18 |
12 |
p. 1637-1651
|
article
|
| 42 |
Possible origin of ovarian cancer in the fallopian tubes
|
Venkatesan, Priya
|
|
2017
|
18 |
12 |
p. e714
|
article
|
| 43 |
Quality of life: an important element of treatment value
|
Di Maio, Massimo
|
|
2017
|
18 |
12 |
p. 1557-1558
|
article
|
| 44 |
Questioning the value of margin status in treated cervical precancer
|
Cohen, Paul A
|
|
2017
|
18 |
12 |
p. 1565-1566
|
article
|
| 45 |
Radiotherapy in the setting of breast reconstruction: types, techniques, and timing
|
Ho, Alice Y
|
|
2017
|
18 |
12 |
p. e742-e753
|
article
|
| 46 |
Reducing the global cancer burden among young adults
|
Henderson, Tara O
|
|
2017
|
18 |
12 |
p. 1554-1555
|
article
|
| 47 |
The art of death
|
Kinsey, Caroline A
|
|
2017
|
18 |
12 |
p. 1576
|
article
|
| 48 |
Tobacco control in the UK
|
Burki, Talha Khan
|
|
2017
|
18 |
12 |
p. e715
|
article
|
| 49 |
Towards personalised medicine in lung and thymus neuroendocrine tumours
|
Pelosi, Giuseppe
|
|
2017
|
18 |
12 |
p. 1563-1565
|
article
|
Journal description